TIS 0.00% 0.0¢ tissue therapies limited

great annual report, page-2

  1. 120 Posts.
    this should be the last hurdle , if you can call it that...
    and we should be off to town...

    During January 2010 Tissue Therapies executed a contract with Cardiff University for Professor Keith Harding to
    conduct a human trial of VitroGro for completion at the end of December 2010.
    This clinical trial will be used to produce the final data necessary for the approval of VitroGro for sale in Europe,
    Britian, Canada, Australia and New Zealand, with subsequent rollout planned for the rest of the world.
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.